Zobrazeno 1 - 10
of 46
pro vyhledávání: '"Ana Planinc Peraica"'
Autor:
Martina Bogeljić Patekar, Vibor Milunović, Karla Mišura Jakobac, Dražen Perica, Inga Mandac Rogulj, Marin Kursar, Ana Planinc-Peraica, Slobodanka Ostojić Kolonić
Publikováno v:
Acta Clinica Croatica, Vol 57., Iss 3., Pp 542-553 (2018)
The aim of this review is to present data on bendamustine, a non-cross resistant alkylating agent, alone or in combination for treatment of non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Bendamustine is currently approved for ritu
Externí odkaz:
https://doaj.org/article/a532d7dede5040d49da04c819b38aa99
Autor:
Vibor Milunović, Martina Bogeljić Patekar, Karla Mišura Jakubac, Inga Mandac Rogulj, Delfa Radić-Krišto, Ana Planinc-Peraica, Slobodanka Ostojić Kolonić
Publikováno v:
Acta Clinica Croatica, Vol 56., Iss 1., Pp 143-156 (2017)
Rituximab is a chimeric monoclonal CD20 antibody used in the treatment of CD20 positive non-Hodgkin lymphomas and has revolutionized treatment approach to these hematologic malignancies in the last decade. The main aim of this review is to present da
Externí odkaz:
https://doaj.org/article/56a6185676fe49db91e004668b948a8e
Autor:
Dean Mileta, Ingrid Prkačin, Ana Planinc Peraica, Gordana Cavrić, Inga Mandac Rogulj, Višnja Mandac Bajan
Publikováno v:
Liječnički vjesnik. 141:247-249
Myelodysplastic syndromes (MDS) are a group of clonal disorders arising from hematopoietic stem cells and are generally characterized by inefficient hematopoiesis and dysplasia. The International Prognostic Scoring Sytem (IPSS) is an important standa
Autor:
Ana Reschner, Delfa Radić-Krišto, Slobodanka Ostojić Kolonić, Inga Mandac Rogulj, Gordana Kaić, Marin Kursar, Marko Martinović, Morana Kosanović-Bajić, Ana Planinc-Peraica
Publikováno v:
Liječnički vjesnik. 141
Autor:
Ingrid Prkačin, Inga Mandac Rogulj, Višnja Mandac Bajan, Ana Planinc Peraica, Gordana Cavrić, Dean Mileta
Publikováno v:
Liječnički vjesnik
Volume 141
Issue 7-8
Volume 141
Issue 7-8
Mijelodisplastični sindrom (MDS) grupa je klonskih mijeloidnih poremećaja s heterogenom kliničkom slikom, a najveći broj komplikacija posljedica je citopenija koje su karakteristično obilježje. Etiologija nije dovoljno poznata. Internacionalni
Autor:
Slobodanka Ostojić, Ekaterina Bulycheva, Ana Planinc-Peraica, Vibor Milunović, Inga Mandac Rogulj
Publikováno v:
European Journal of Haematology. 96:553-563
Myelodysplastic syndromes (MDS) are heterogeneous group of hematologic disorders of mostly elderly and based on distinct clinical phenotypes. Current paradigm of their pathogenesis relies on somatic gene mutations combined with the predisposing defec
Autor:
Karla Mišura Jakobac, Ana Planinc-Peraica, Marin Kursar, Inga Mandac Rogulj, Dražen Perica, Vibor Milunović, Martina Bogeljić Patekar, Slobodanka Ostojić Kolonić
Publikováno v:
Acta Clinica Croatica
Acta Clinica Croatica, Vol 57, Iss 3., Pp 542-553 (2018)
Acta Clinica Croatica, Vol 57, Iss 3., Pp 542-553 (2018)
SUMMARY – The aim of this review is to present data on bendamustine, a non-cross resistant alkylating agent, alone or in combination for treatment of non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Bendamustine is currently appro
Autor:
Martina Bogeljić Patekar, Vibor Milunović, Karla Mišura Jakobac, Dražen Perica, Inga Mandac Rogulj, Marin Kursar, Ana Planinc-Peraica, Slobodanka Ostojić Kolonić
Publikováno v:
Acta clinica Croatica
Volume 57.
Issue 3.
Volume 57.
Issue 3.
The aim of this review is to present data on bendamustine, a non-cross resistant alkylating agent, alone or in combination for treatment of non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Bendamustine is currently approved for ritu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::aad5ca23ab7ca79428ebc324897596b2
https://www.bib.irb.hr/1089253
https://www.bib.irb.hr/1089253
Autor:
Ana Planinc-Peraica, Slobodanka Ostojić Kolonić, Inga Mandac Rogulj, Vibor Milunović, Karla Mišura Jakubac, Delfa Radić-Krišto, Martina Bogeljić Patekar
Publikováno v:
Acta Clinica Croatica, Vol 56., Iss 1., Pp 143-156 (2017)
Rituximab is a chimeric monoclonal CD20 antibody used in the treatment of CD20 positive non-Hodgkin lymphomas and has revolutionized treatment approach to these hematologic malignancies in the last decade. The main aim of this review is to present da
Autor:
VIBOR MILUNOVIĆ, MARTINA BOGELJIĆ PATEKAR, NIKOLA ZAGORAC, DRAŽEN PERICA, INGA MANDAC ROGULJ, IKA KARDUM-SKELIN, ANA PLANINC-PERAICA, SLOBODANKA OSTOJIĆ KOLONIĆ
Publikováno v:
Acta medica Croatica : Časopis Akademije medicinskih znanosti Hrvatske
Volume 71
Issue 1
Volume 71
Issue 1
Cilj ovog rada bio je prikazati rezultate liječenja bolesnika s relapsnim ili refraktornim klasičnim Hodgkinovim limfomom visokodoznom kemoterapijom praćenom autolognom transplantacijom matičnih stanica u jednoj ustanovi. U retrospektivno istraž